Legend Biotech shares may face volatility as the company seeks a permanent replacement for outgoing CEO Ying Huang.
Legend Biotech (LEGN) announced the immediate departure of CEO Ying Huang, who has also stepped down from the board of directors as of July 24, 2026. The company did not disclose a reason for the exit but confirmed the board has begun a comprehensive search for a permanent successor.
Huang had led Legend Biotech since 2017, overseeing its transition into a clinical-stage biopharmaceutical firm focused on cell therapy. The company’s shares have seen fluctuations amid pipeline developments and regulatory updates in recent quarters.
Legend Biotech stated it will provide further updates on the leadership transition as the search progresses.